Sign inJoin waitlistJoin the waitlist

Michael Rosenzweig

Hematologist-Oncologist · City of Hope National Medical Center

Credentials: · · · · · ·

History

City of Hope National Medical Center
Present

Hematology and Medical Oncology
2004–2007
Internal Medicine
2001–2004
University of Arizona College of Medicine
1997–2001

Research

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection
Science · 1998 · 1,171 citations
Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species
Nature Medicine · 1997 · 864 citations
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
New England Journal of Medicine · 2021 · 562 citations

Amrita Krishnan
14 papers
Stephen Forman
11 papers
Steven Rosen
9 papers
MH
Maung Htut
8 papers
RC
Raymond Comenzo
8 papers
SG
Scott Goldsmith
8 papers
Vaishali Sanchorawala
8 papers
NN
Nitya Nathwani
7 papers
FS
Firoozeh Sahebi
6 papers
HL
Heather Landau
6 papers
Jason Valent
6 papers
CK
Chatchada Karanes
5 papers

Grants

Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans
National Cancer Institute · R01
PI · $2.7M · Beckman Research Institute/City of Hope
2021–2027
Safe and Effective Anti CD154 Antibodies for Therapeutic Intervention
National Institute of Allergy and Infectious Diseases · R44
Contact PI · $998K · Immunext, Inc.
2012–2016
VISTA: A Novel Therapeutic Target That Negatively Regulates Immunity
National Institute of Allergy and Infectious Diseases · R43
Contact PI · $300K · Immunext, Inc.
2011–2014
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $10.1K · Boston University Medical Campus
2005–2007

Clinical trials

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2022–2028
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Principal investigator · Active not recruiting · Phase 2
City of Hope Medical Center
2022–2027
Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis
Principal investigator · Unknown · Phase 1, Phase 2
Sorrento Therapeutics, Inc.
2021–2024
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Principal investigator · Recruiting · Phase 2
City of Hope Medical Center
2020–2027